{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/rxrx-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/rxrx-stock-analysis/data.json",
 "title": "Recursion (RXRX) Stock Forecast & Price Target (2026)",
 "description": "Recursion Pharmaceuticals, Inc. (RXRX) stock: Healthcare, Biotechnology. $2.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Recursion Pharmaceuticals, Inc. (RXRX)",
 "published": "2026-07-21T09:30:09+00:00",
 "modified": "2026-09-27T02:25:54.376+00:00",
 "generated": "2026-09-27T15:20:49.097Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "RXRX",
  "name": "Recursion Pharmaceuticals, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.recursion.com"
 },
 "quote": {
  "price": 3.74,
  "previousClose": 3.89,
  "change": -0.15,
  "changePercent": -3.86,
  "open": 3.89,
  "high": 3.9,
  "low": 3.7,
  "volume": 10433200,
  "averageVolume": 24800570,
  "marketCap": 2005653865,
  "fiftyTwoWeekHigh": 7.18,
  "fiftyTwoWeekLow": 2.77,
  "marketOpen": false,
  "asOf": "2026-09-27T02:25:54.000Z"
 },
 "statistics": {
  "pe": -2.5972222288449607,
  "eps": -1,
  "dividendYield": 0,
  "beta": 1.071,
  "priceToSales": 36.562157,
  "priceToBook": 2.1871345,
  "revenueTtm": 54856000,
  "grossMargin": -0.5734629604272217,
  "returnOnEquity": -0.5658
 },
 "technicals": {
  "rsi": 52.21,
  "macd": 0.14,
  "sma50": 3.32,
  "sma200": 3.59,
  "rsiSignal": "Neutral",
  "trend": "Bearish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 59,
  "consensus": "Hold",
  "fairValue": 7,
  "analystTarget": 7,
  "analystCount": 7,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-27T02:25:54.000Z",
  "priceAtAnalysis": 3.74,
  "volatility": {
   "daily": 5.49,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 3.7,
  "aggressiveEntry": 3.74,
  "stopLoss": 3.4,
  "stopLossPercent": 8.23,
  "targets": [
   3.81,
   3.89,
   4
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 1.71,
    "base": 3.24,
    "upside90th": 6.15
   },
   {
    "year": 2028,
    "downside10th": 1.13,
    "base": 2.8,
    "upside90th": 6.94
   },
   {
    "year": 2029,
    "downside10th": 0.8,
    "base": 2.43,
    "upside90th": 7.37
   },
   {
    "year": 2030,
    "downside10th": 0.58,
    "base": 2.1,
    "upside90th": 7.57
   },
   {
    "year": 2031,
    "downside10th": 0.43,
    "base": 1.82,
    "upside90th": 7.63
   },
   {
    "year": 2032,
    "downside10th": 0.33,
    "base": 1.58,
    "upside90th": 7.57
   },
   {
    "year": 2033,
    "downside10th": 0.25,
    "base": 1.37,
    "upside90th": 7.44
   },
   {
    "year": 2034,
    "downside10th": 0.19,
    "base": 1.18,
    "upside90th": 7.24
   },
   {
    "year": 2035,
    "downside10th": 0.15,
    "base": 1.02,
    "upside90th": 7
   },
   {
    "year": 2036,
    "downside10th": 0.12,
    "base": 0.89,
    "upside90th": 6.72
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "RXRX Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$3.89",
    "Day Range": "$3.70 to $3.90",
    "Prev Close": "$3.89",
    "Volume": "10.43M",
    "52-Week Range": "$2.77 to $7.18",
    "Market Cap": "$2.01B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis On price-to-sales, the yardstick used here in place of P/E, RXRX trades at 36.56x, far above the sector average of 3.70x."
   ]
  },
  {
   "id": "financials",
   "title": "RXRX Financial Performance",
   "text": [
    "Analysis: In the last 3 quarters, RXRX beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "RXRX Analysis",
   "text": [
    "Recursion Pharmaceuticals is currently trading above its 50-day and 200-day moving averages ($3.32 and $3.59), with its price also positioned above the 20-day Exponential Moving Average, suggesting a neutral to slightly positive short-term trend. The Relative Strength Index (RSI) is at 52.21, indicating neutral momentum, neither overbought nor oversold. The MACD is slightly positive at 0.137, hinting at a potential shift in momentum. Key support levels are indicated by the 50-day SMA at $3.32 and the 200-day SMA at $3.59, while the 20-day EMA sits at $3.57. The current price of $3.74 is testing resistance near its recent highs. Volume has been below average recently, down 57.9% from its average, which could suggest a lack of conviction behind the current price action. The overall chart structure suggests a period of consolidation as the stock attempts to build a base above its key moving averages.",
    "Analysts project revenue growth of +152.00% year-over-year for the current quarter, indicating strong potential for top-line expansion.",
    "The median analyst price target of $7.00 represents an 87.2% upside from the current stock price, suggesting potential for significant price appreciation.",
    "Insiders have sold over $13.2 million worth of stock with no reported purchases, indicating a 'Moderate Sell Signal' and potential lack of confidence.",
    "The company continues to report net losses, with a negative EPS of -1.00 for the latest reported period, raising concerns about long-term profitability.",
    "The base case outlook for Recursion Pharmaceuticals anticipates a potential recovery driven by projected revenue growth and analyst price targets suggesting significant upside. The median analyst target price of $7.00 implies an 87.2% increase from the current price, reflecting optimism about the company's long-term potential in the biotechnology space. Analysts forecast revenue growth of 35.3% for the current year, signaling a potential shift towards commercialization and increased sales. However, the path forward is fraught with risk. The company's persistent losses, negative EPS, and moderate insider selling present significant headwinds. A key factor to watch will be the company's ability to translate projected revenue growth into profitability and manage its cash burn effectively. Failure to do so, or a continuation of insider selling, could lead to a downside scenario, with Monte Carlo simulations suggesting a potential price drop to $0.58 by 2030."
   ],
   "lists": {
    "ProTips": [
     "Insider selling totaling over $13.2 million suggests caution, despite the 'Hold' consensus from Wall Street analysts.",
     "The stock is trading above key moving averages (50-day and 200-day SMA), indicating neutral to positive short-term momentum, but volume is below average.",
     "Given the company's ongoing losses and high valuation multiples, investors should consider position sizing carefully and monitor revenue growth trends closely."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Revenue Growth Estimates for Current Quarter",
     "text": "Analysts project revenue growth of +152.00% year-over-year for the current quarter, indicating strong potential for top-line expansion.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Bullish",
     "title": "Upside Potential to Median Analyst Price Target",
     "text": "The median analyst price target of $7.00 represents an 87.2% upside from the current stock price, suggesting potential for significant price appreciation.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Signal",
     "text": "Insiders have sold over $13.2 million worth of stock with no reported purchases, indicating a 'Moderate Sell Signal' and potential lack of confidence.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Persistent Net Losses and Negative EPS",
     "text": "The company continues to report net losses, with a negative EPS of -1.00 for the latest reported period, raising concerns about long-term profitability.",
     "source": "Company Financials"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Recursion Pharmaceuticals exhibits a high price-to-sales ratio of 36.56, significantly above the sector median of 3.7, indicating that the stock is richly valued relative to its current sales. The company's negative EPS of -1.00 means its P/E ratio is not applicable, and its profit margin of 4.45% is considerably lower than the sector median of 6.9%. Despite these valuation concerns, analysts project substantial revenue growth for the current quarter, with estimates showing a +152.00% year-over-year increase, though the next quarter's estimate shows a significant decline. The company's balance sheet appears relatively strong with a low debt-to-equity ratio of 0.07, suggesting minimal financial leverage. However, its return on equity is significantly negative at -56.58%, highlighting ongoing profitability challenges. The current valuation metrics suggest that the market is pricing in significant future growth, which is not yet reflected in current profitability or sales trends.",
    "Recursion Pharmaceuticals reported a loss of -$0.25 per share for the quarter ending June 2026, missing the analyst estimate of -$0.23 by 8.7%, and the stock saw a modest 0.32% increase following the announcement. This follows a pattern of consistent losses, with the company missing estimates in the prior quarter as well, though it has shown some positive surprise percentages in earlier periods. Revenue for the current quarter is estimated to grow significantly by 152.00% year-over-year, indicating a potential turnaround in top-line performance, but forward-looking estimates for the next quarter show a sharp contraction.",
    "Recursion Pharmaceuticals faces significant risks, including its ongoing unprofitability, evidenced by a negative EPS and a substantial operating margin loss, which contrasts with its high price-to-sales ratio. Moderate insider selling, with over $13.2 million in sales versus no reported purchases, signals a lack of confidence from management. Also, the company's revenue growth has been sharply negative at -60.1%, raising concerns about its ability to achieve sustainable growth despite optimistic near-term revenue estimates."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "2.01B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-1.00"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "7.18"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "2.77"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Bearish Price vs SMA Bullish MACD Bullish Moving averages show a lagging Death Cross (50-day: $3.315, 200-day: $3.586), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bearish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "52.21"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "0.14"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "3.32"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "3.59"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.54",
    "Correlation with Nasdaq 100 (QQQ)": "+0.54",
    "Correlation with Bitcoin (BTC)": "+0.25",
    "Correlation with Gold (XAU)": "+0.18"
   }
  },
  {
   "id": "trade-plans",
   "title": "RXRX Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (52.2) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$3.814",
    "TARGET 2": "$3.888",
    "TARGET 3": "$3.999",
    "STOP LOSS": "$3.398"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-5.70%",
    "Average Feb return": "+3.25%",
    "Average Mar return": "-21.38%",
    "Average Apr return": "-6.20%",
    "Average May return": "+6.11%",
    "Average Jun return": "+8.04%",
    "Average Jul return": "+13.94%",
    "Average Aug return": "-5.83%",
    "Average Sep return": "-2.44%",
    "Average Oct return": "-6.19%",
    "Average Nov return": "+2.80%",
    "Average Dec return": "-0.54%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "5.49%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in RXRX in April 2021 would be worth about $1,195 today, compared with about $18,486 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in RXRX today could grow to about $2,370 by 2036 in the base case, with a bull case near $17,979 and a bear case around $312. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "RXRX Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $2.10 for RXRX by 2030 in the base case, from $3.74 today (0.6x over 4 years). The downside path ends near $0.5837. These are outcomes of a Monte Carlo simulation run on RXRX's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using RXRX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "RXRX simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$1.71",
        "$3.24",
        "$6.15"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$1.13",
        "$2.80",
        "$6.94"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$0.8003",
        "$2.43",
        "$7.37"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$0.5837",
        "$2.10",
        "$7.57"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$0.4344",
        "$1.82",
        "$7.63"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$0.3281",
        "$1.58",
        "$7.57"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$0.2505",
        "$1.37",
        "$7.44"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$0.193",
        "$1.18",
        "$7.24"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$0.1497",
        "$1.02",
        "$7.00"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$0.1168",
        "$0.8863",
        "$6.72"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "JNJ Johnson & Johnson NYSE $271.22 +0.20%",
     "url": "https://clearank.com/stock/johnson-johnson-jnj/"
    },
    {
     "text": "QDEL QuidelOrtho Corporation NASDAQ $10.94 +2.34%",
     "url": "https://clearank.com/stock/quidelortho-qdel/"
    },
    {
     "text": "AGL agilon health, Inc. NYSE $80.73 +6.46%",
     "url": "https://clearank.com/stock/agl-stock-analysis/"
    },
    {
     "text": "CRSP CRISPR Therapeutics AG NASDAQ $54.23 -2.64%",
     "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
    },
    {
     "text": "PFE Pfizer Inc. NYSE $28.67 +0.92%",
     "url": "https://clearank.com/stock/pfizer-pfe/"
    },
    {
     "text": "IDXX IDEXX Laboratories, Inc. NASDAQ $519.26 +1.14%",
     "url": "https://clearank.com/stock/idxx-stock-analysis/"
    },
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $435.61 +2.86%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "TLRY Tilray Brands Inc. NASDAQ $4.13 +1.47%",
     "url": "https://clearank.com/stock/tilray-brands-tlry/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "Workday (WDAY) vs Atlassian (TEAM) Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/workday-vs-atlassian/"
    },
    {
     "text": "V vs MA Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/v-vs-ma/"
    },
    {
     "text": "QBTS vs QUBT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/qbts-vs-qubt/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "RXRX Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$13.2M",
    "Insiders": "12",
    "Avg Transaction": "$338.7K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in RXRX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Jan 14, 2022",
       "cells": [
        "GIBSON CHRISTOPHER Chief Executive Officer",
        "Sell",
        "341.0K",
        "$4.7M"
       ]
      },
      {
       "label": "Aug 11, 2025",
       "cells": [
        "GIBSON CHRISTOPHER Chief Executive Officer",
        "Sell",
        "618.2K",
        "$3.3M"
       ]
      },
      {
       "label": "Mar 7, 2022",
       "cells": [
        "GIBSON CHRISTOPHER Chief Executive Officer",
        "Sell",
        "300.0K",
        "$2.2M"
       ]
      },
      {
       "label": "Mar 15, 2022",
       "cells": [
        "GIBSON CHRISTOPHER Chief Executive Officer",
        "Sell",
        "336.2K",
        "$2.2M"
       ]
      },
      {
       "label": "Jul 13, 2023",
       "cells": [
        "BURRELL TERRY-ANN Director",
        "Sell",
        "117.0K",
        "$1.4M"
       ]
      },
      {
       "label": "Apr 4, 2024",
       "cells": [
        "GIBSON CHRISTOPHER C Chief Executive Officer",
        "Sell",
        "130.0K",
        "$1.2M"
       ]
      },
      {
       "label": "Feb 22, 2022",
       "cells": [
        "GIBSON CHRISTOPHER Chief Executive Officer",
        "Sell",
        "100.0K",
        "$1.0M"
       ]
      },
      {
       "label": "Dec 2, 2025",
       "cells": [
        "BORGESON BLAKE CHARLES Director",
        "Sell",
        "220.0K",
        "$961.4K"
       ]
      },
      {
       "label": "Jan 6, 2026",
       "cells": [
        "BORGESON BLAKE CHARLES Director",
        "Sell",
        "220.0K",
        "$959.2K"
       ]
      },
      {
       "label": "Feb 3, 2026",
       "cells": [
        "BORGESON BLAKE CHARLES Director",
        "Sell",
        "220.0K",
        "$924.0K"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Recursion+Pharmaceuticals%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Recursion Pharmaceuticals' stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Recursion Pharmaceuticals' stock price is projected to be $2.10 in 2030 under a base case scenario. The downside projection is $0.58, while the upside projection reaches $7.57. These figures represent statistical outcomes and are not definitive price targets."
  },
  {
   "question": "Is Recursion Pharmaceuticals stock a buy right now?",
   "answer": "Recursion Pharmaceuticals holds a 'Hold' consensus rating from Wall Street analysts, supported by a median price target of $7.00, which suggests significant upside potential. However, the company's persistent losses and moderate insider selling present considerable risks that temper a strong buy recommendation."
  },
  {
   "question": "What are the key technical levels for Recursion Pharmaceuticals stock?",
   "answer": "Recursion Pharmaceuticals is currently trading above its 50-day SMA ($3.32) and 200-day SMA ($3.59), indicating support at these levels. The RSI is neutral at 52.21, suggesting no immediate overbought or oversold conditions."
  },
  {
   "question": "What is the insider sentiment for Recursion Pharmaceuticals?",
   "answer": "Insider sentiment for Recursion Pharmaceuticals is currently a 'Moderate Sell Signal,' with over $13.2 million in sales reported by insiders versus no reported purchases. This indicates a net selling pressure from management."
  },
  {
   "question": "How does Recursion Pharmaceuticals compare to its sector averages?",
   "answer": "Recursion Pharmaceuticals' price-to-sales ratio of 36.56 is significantly higher than the sector median of 3.7. Its negative return on equity of -56.58% also lags behind the sector median of 6.9%, though its debt-to-equity ratio of 0.07 is lower than the sector average."
  },
  {
   "question": "What are the recent earnings trends for Recursion Pharmaceuticals?",
   "answer": "Recursion Pharmaceuticals reported a loss of -$0.25 per share for the quarter ending June 2026, missing analyst estimates. While revenue is projected to grow significantly year-over-year for the current quarter, the company has a history of losses and missed earnings expectations."
  },
  {
   "question": "What is the outlook for Recursion Pharmaceuticals' revenue growth?",
   "answer": "Analysts project substantial revenue growth for Recursion Pharmaceuticals in the current quarter, with estimates indicating a 152.00% year-over-year increase. However, projections for the next quarter show a significant contraction, suggesting potential volatility in top-line performance."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "JNJ",
    "name": "Johnson & Johnson NYSE",
    "price": "$271.22",
    "change": "+0.20%",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "QDEL",
    "name": "QuidelOrtho Corporation NASDAQ",
    "price": "$10.94",
    "change": "+2.34%",
    "url": "https://clearank.com/stock/quidelortho-qdel/"
   },
   {
    "ticker": "AGL",
    "name": "agilon health, Inc. NYSE",
    "price": "$80.73",
    "change": "+6.46%",
    "url": "https://clearank.com/stock/agl-stock-analysis/"
   },
   {
    "ticker": "CRSP",
    "name": "CRISPR Therapeutics AG NASDAQ",
    "price": "$54.23",
    "change": "-2.64%",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "PFE",
    "name": "Pfizer Inc. NYSE",
    "price": "$28.67",
    "change": "+0.92%",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   },
   {
    "ticker": "IDXX",
    "name": "IDEXX Laboratories, Inc. NASDAQ",
    "price": "$519.26",
    "change": "+1.14%",
    "url": "https://clearank.com/stock/idxx-stock-analysis/"
   },
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$435.61",
    "change": "+2.86%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "TLRY",
    "name": "Tilray Brands Inc. NASDAQ",
    "price": "$4.13",
    "change": "+1.47%",
    "url": "https://clearank.com/stock/tilray-brands-tlry/"
   }
  ],
  "comparisons": [
   {
    "ticker": "Workday (WDAY) vs Atlassian (TEAM) Comparison",
    "name": "",
    "url": "https://clearank.com/compare/workday-vs-atlassian/"
   },
   {
    "ticker": "V vs MA Comparison",
    "name": "",
    "url": "https://clearank.com/compare/v-vs-ma/"
   },
   {
    "ticker": "QBTS vs QUBT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/qbts-vs-qubt/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   },
   {
    "ticker": "CDE",
    "text": "Coeur Mining Inc.",
    "url": "https://clearank.com/stock/cde-stock-analysis/"
   },
   {
    "ticker": "CCI",
    "text": "Crown Castle Inc.",
    "url": "https://clearank.com/stock/cci-stock-analysis/"
   },
   {
    "ticker": "AME",
    "text": "AMETEK Inc",
    "url": "https://clearank.com/stock/ame-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 8.20%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   },
   {
    "ticker": "TWLO",
    "text": "↓ 7.96%",
    "url": "https://clearank.com/stock/twlo-stock-analysis/"
   },
   {
    "ticker": "CRDO",
    "text": "↑ 7.65%",
    "url": "https://clearank.com/stock/credo-crdo/"
   },
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   },
   {
    "ticker": "GRT/USD",
    "text": "↑ 20.82%",
    "url": "https://clearank.com/crypto/the-graph-grt/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "REGN",
    "text": "Regeneron Pharmaceuticals",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "REPL",
    "text": "Replimune",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "RGNX",
    "text": "REGENXBIO",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/"
   },
   {
    "ticker": "VKTX",
    "text": "Viking Therapeutics Inc",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   },
   {
    "ticker": "VRTX",
    "text": "Vertex Pharmaceuticals",
    "url": "https://clearank.com/stock/vertex-vrtx/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/RXRX-recursion-pharmaceuticals-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/RXRX-recursion-pharmaceuticals-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Recursion Pharmaceuticals (RXRX) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/rxrx-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/rxrx-stock-analysis/",
        "name": "Recursion (RXRX) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/rxrx-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/rxrx-stock-analysis/",
     "name": "Recursion (RXRX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-21T09:30:09+00:00",
     "dateModified": "2026-09-27T02:25:54+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/RXRX-recursion-pharmaceuticals-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/rxrx-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/rxrx-stock-analysis/#richSnippet",
     "headline": "Recursion (RXRX) Stock Forecast & Price Target (2026)",
     "name": "Recursion (RXRX) Stock Forecast & Price Target (2026)",
     "description": "Recursion Pharmaceuticals, Inc. (RXRX) stock: Healthcare, Biotechnology. $2.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-21T09:30:09+00:00",
     "dateModified": "2026-09-27T02:25:54+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Recursion Pharmaceuticals, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "RXRX"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "Recursion Pharmaceuticals, Inc. Class A Common Stock represents ownership in Recursion Pharmaceuticals, a clinical-stage TechBio company focused on industrializing drug discovery through data-driven biology and chemistry. The company uses automation, artificial intelligence, machine learning, and en",
      "tickerSymbol": "RXRX",
      "sameAs": "https://www.recursion.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/rxrx-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/RXRX-recursion-pharmaceuticals-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/rxrx-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Recursion Pharmaceuticals' stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Recursion Pharmaceuticals' stock price is projected to be $2.10 in 2030 under a base case scenario. The downside projection is $0.58, while the upside projection reaches $7.57. These figures represent statistical outcomes and are not definitive price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is Recursion Pharmaceuticals stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Recursion Pharmaceuticals holds a 'Hold' consensus rating from Wall Street analysts, supported by a median price target of $7.00, which suggests significant upside potential. However, the company's persistent losses and moderate insider selling present considerable risks that temper a strong buy recommendation."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical levels for Recursion Pharmaceuticals stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Recursion Pharmaceuticals is currently trading above its 50-day SMA ($3.32) and 200-day SMA ($3.59), indicating support at these levels. The RSI is neutral at 52.21, suggesting no immediate overbought or oversold conditions."
     }
    },
    {
     "@type": "Question",
     "name": "What is the insider sentiment for Recursion Pharmaceuticals?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider sentiment for Recursion Pharmaceuticals is currently a 'Moderate Sell Signal,' with over $13.2 million in sales reported by insiders versus no reported purchases. This indicates a net selling pressure from management."
     }
    },
    {
     "@type": "Question",
     "name": "How does Recursion Pharmaceuticals compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Recursion Pharmaceuticals' price-to-sales ratio of 36.56 is significantly higher than the sector median of 3.7. Its negative return on equity of -56.58% also lags behind the sector median of 6.9%, though its debt-to-equity ratio of 0.07 is lower than the sector average."
     }
    },
    {
     "@type": "Question",
     "name": "What are the recent earnings trends for Recursion Pharmaceuticals?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Recursion Pharmaceuticals reported a loss of -$0.25 per share for the quarter ending June 2026, missing analyst estimates. While revenue is projected to grow significantly year-over-year for the current quarter, the company has a history of losses and missed earnings expectations."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for Recursion Pharmaceuticals' revenue growth?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Analysts project substantial revenue growth for Recursion Pharmaceuticals in the current quarter, with estimates indicating a 152.00% year-over-year increase. However, projections for the next quarter show a significant contraction, suggesting potential volatility in top-line performance."
     }
    }
   ]
  }
 ]
}